Armata Pharmaceuticals, Inc. 8K

Armata Pharmaceuticals reported key regulatory, manufacturing and funding milestones supporting a second-half 2026 Phase 3 start for AP-SA02 and promoted David House to Chief Financial Officer.

Armata Pharmaceuticals, Inc. announced significant clinical, regulatory, manufacturing, and operational progress in advancing its intravenously administered multi-phage product candidate AP-SA02 toward a planned Phase 3 superiority study for adjunct treatment of complicated Staphylococcus aureus bacteremia, including submission to the FDA of the complete Phase 3 protocol and comprehensive responses to all End-of-Phase 2 feedback, completion of four engineering manufacturing runs at its in-house cGMP facility with clinical trial material production as the next step, receipt of an additional $2.5 million under its existing U.S. Department of Defense award (bringing total funding under that award to $28.7 million) to support Phase 3 readiness, and the promotion of David House to Chief Financial Officer, while reaffirming its goal to initiate the pivotal Phase 3 study in the second half of 2026 to support a future BLA filing for AP-SA02.

Filing Facts

CIK

921114

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-084861

Alert Tier

6